Cytokines, chemokines and other effector molecules involved in meningococcal disease

Journal of Medical Microbiology

Volumn 50, Issue 10, 2001, Pages 847-859

  Hackett, S J ^a   Thomson, A P J ^a   Hart, C A ^a  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; COLONY STIMULATING FACTOR 1; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA;

DISEASE MODEL; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; MENINGOCOCCOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 0034807835     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-50-10-847     Document Type: Review

References (102)

1. Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience
2. The changing presentations of meningococcal disease
3. Meningococcal meningitis in sub-Saharan Africa: A model for the epidemic process
4. Potent stimulation of human macrophages by lipopolysaccharide-deficient Neisseria meningitidis
5. Gram-negative bacteria induce pro-inflammatory cytokine production by monocytes in the absence of lipopolysaccharide (LPS)
6. Expression of tumor necrosis factor-alpha and transforming growth factor-beta 1 in cerebrospinal fluid cells in meningitis
7. Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia
8. Tumour necrosis factor alpha antibody protects against lethal meningococcaemia
9. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition
10. Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors
11. Prostaglandins E2 and I2, interleukin 1-beta, and tumor necrosis factor in cerebrospinal fluid in infants and children with bacterial meningitis
12. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome
13. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura
14. Different role of cytokine mediators in septic shock related to meningococcal disease and surgery/polytrauma
15. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia
16. Plasma patterns of tumor necrosis factor-alpha (TNF) and TNF soluble receptors during acute meningococcal infections and the effect of plasma exchange
17. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections
18. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock
19. Hypoglycemia, hormones and cytokines in fatal meningococcal septicemia
20. Release of tumor necrosis factor: An innate host characteristic that may contribute to the outcome of meningococcal disease
21. Posttranscriptional down-regulation of tumor necrosis factor-alpha and interleukin-1beta production in acute meningococcal infections
22. Dynamics of blood cytokine concentrations in patients with bacteremic infections
23. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock
24. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia
25. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia
26. An interleukin-6-induced acute-phase response does not confer protection against lipopolysaccharide lethality
27. The role of IFN-gamma in the pathology of experimental endotoxemia
28. IL-10 inhibits cytokine production by activated macrophages
29. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles
30. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease
31. Genetic influence on cytokine production and fatal meningococcal disease
32. Endotoxin in meningococcal infections
33. Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: Synergistic effect with interleukin 1 and tumor necrosis factor
34. Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice
35. Genetic influence on cytokine production in meningococcal disease
36. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease
37. Relevance of the tumor necrosis factor alpha (TNF alpha)-308 promoter polymorphism in TNF alpha gene regulation
38. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1beta and interleukin 6 appearance during lethal bacteremia
39. Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice
40. The pattern of interleukin-1beta (IL-1beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections
41. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response
42. Cytokine-associated tissue injury and lethality in mice: A comparative study
43. Complement activation in relation to capillary leakage in children with septic shock and purpura
44. Interleukin-6 and its soluble receptor during acute meningococcal infections: Effect of plasma or whole blood exchange
45. Lack of correlation between soluble CD14 and IL-6 in meningococcal septic shock
46. Increased plasma levels of interleukin-6 in sepsis
47. Positive and negative regulation of interleukin-12 gene expression
48. Interleukin-12: A cytokine at the interface of inflammation and immunity
49. Interleukin 12 levels during the initial phase of septic shock with purpura in children: Relation to severity of disease
50. IFN-gamma-independent production of IL-12 during murine endotoxemia
51. The leukemia inhibitory factor (LIF)
52. ELISA detection of circulating levels of LIF, OSM, and CNTF in septic shock
53. Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids
54. Increased plasma levels of human interleukin for DA1.a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis
55. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10
56. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleukin-10 as a major functional deactivator of human monocytes
57. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
58. Interleukin 10 protects mice from lethal endotoxemia
59. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock
60. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease
61. Proinflammatory and anti-inflammatory cytokines in meningococcal disease
62. High levels of interleukin 10 and tumor necrosis factor alpha in cerebrospinal fluid during the onset of bacterial meningitis
63. Interleukin-10 inhibits the induction of monocyte pro-coagulant activity by bacterial lipopolysaccharide
64. Functions of IL-4 and control of its expression
65. IL-4: Role in disease and regulation of production
66. Interleukin-4 production in response to infection with intracellular bacteria
67. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins
68. Circulating interleukin-6 receptor in patients with sepsis syndrome
69. Soluble interleukin-6 receptor in patients with severe sepsis
70. Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells
71. Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity
72. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity
73. IFN-gamma involvement in the severity of gram-negative infections in mice
74. Participation of IFN-gamma in the pathogenesis of LPS lethality
75. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease
76. The role of RANTES in meningococcal disease
77. Differential alterations in plasma colony-stimulating factor concentrations in meningococcaemia
78. Serum levels of end products of nitric oxide synthesis correlate positively with tumor necrosis factor alpha and negatively with body temperature in patients with postoperative abdominal sepsis
79. Peroxynitrite production by human neutrophils, monocytes and lymphocytes challenged with lipopolysaccharide
80. Nitric oxide as a mediator of reduced arterial responsiveness in septic patients
81. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock
82. Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock
83. Effects of a nitric oxide synthase inhibitor in humans with septic shock
84. Nitric oxide production in meningococcal disease is directly related to disease severity
85. Nitric oxide production in critically ill patients
86. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavourable prognosis
87. Plasma fibronectin concentrations in healthy and septic infants
88. Prognostic value of plasma levels of fibronectin in septic shock
89. Plasma fibronectin in severe infectious purpura of children
90. Fibronectin in meningococcal sepsis. Correlation with antithrombin III and protein C
91. Plasma fibronectin levels in meningococcal disease
92. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease
93. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock
94. Meningococcal disease: Still with us
95. Detection of transforming growth factor beta 1 mRNA in cerebrospinal fluid cells of patients with meningitis by non-radioactive in situ hybridization
96. Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis
97. C-X-C and C-C chemokines are expressed in the cerebrospinal fluid in bacterial meningitis and mediate chemotactic activity on peripheral blood-derived polymorphonuclear and mononuclear cells in vitro
98. Chemokines in the cerebrospinal fluid of patients with meningitis
99. Nitric oxide synthesis in meningococcal meningitis
100. A novel neuronal messenger molecule in brain: The free radical, nitric oxide
101. HMG-1 as a late mediator of endotoxin lethality in mice